May 19, 2015
Local (JPN)

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

Daiichi Sankyo Announces Cooperative Sales Agreement for the Influenza HA Vaccine “Kaketsuken”

Tokyo, Japan (May 19, 2015) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that it has signed a cooperative sales agreement (hereinafter, The Agreement) with The Chemo-Sero-Therapeutic Research Institute (hereinafter, Kaketsuken) on May 18, 2015, for its influenza HA vaccine “Kaketsuken” (hereinafter, The Vaccine).

 

The Vaccine is an egg-based, inactivated vaccine used for prevention of seasonal influenza. Based on The Agreement, Daiichi Sankyo will begin sales activities of The Vaccine from next season (2015-2016).

 

In addition, Daiichi Sankyo will continue to sell its current influenza HA vaccine, “Kitasatodaiichisankyo”.

 

Daiichi Sankyo is committed to the prevention of seasonal influenza through The Vaccine, as well as to contributing to public health and preventive medicine in Japan through the provision of vaccines which fulfill unmet medical needs.

 

Product Overview

 

Name

Influenza HA vaccine “Kaketsuken”

Generic Name

Influenza HA vaccine

Classification

Biological product, powerful medicine, prescription medicine (Caution: To be prescribed by a doctor or other medical professional)

Content

Bottled 1mL: 2 bottles

Indication

Prevention of influenza

Dosage / Administration

For children age 6 months to 3 years, administer 0.25mL dose subcutaneously. For children age 3 to 13, administer two 0.5mL doses subcutaneously, with an interval of 2 to 4 weeks between administrations. For people over the age of 13, administer one 0.5mL dose or two 0.5mL doses subcutaneously with an interval of 1 to 4 weeks between administrations.

Manufacturer / Seller

The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)

Seller

Daiichi Sankyo Company, Limited

Cooperative Seller

Japan Vaccine Co., Ltd.